Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Date:10/30/2008

with our plan to bring picoplatin to the market in 2010.

Third Quarter 2008 Unaudited Financial Results

Cash and investment securities as of September 30, 2008, were $84.0 million, compared with $92.6 million at December 31, 2007. Management believes that the existing cash and investment securities will be adequate to fund the Company's operations at least through the first quarter of 2010.

The Company reported a net loss of $12.2 million ($0.36 diluted loss per share on a loss applicable to common shares of $12.4 million) for the third quarter of 2008 compared with a net loss of $7.0 million ($0.20 diluted loss per share on a loss applicable to common shares of $7.1 million) for the third quarter of 2007. The Company reported a net loss of $34.6 million ($1.01 diluted loss per share on a loss applicable to common shares of $35.0 million) for the nine months ended September 30, 2008, compared with a net loss of $23.2 million ($0.80 diluted loss per share on a loss applicable to common shares of $23.6 million) for the same period in 2007.

There was no revenue for the three and nine months ended September 30, 2008 and 2007.

Total operating expenses for the third quarter of 2008 increased 58 percent to $12.4 million, from $7.9 million for the third quarter of 2007, and increased 44 percent to $35.8 million for the nine months ended September 30, 2008, from $24.9 million for the same period in 2007.

Research and development (R&D) expenses increased 79 percent to $9.0 million for the third quarter of 2008, from $5.1 million for the third quarter of 2007 and increased 50 percent to $24.5 million for the nine months ended September 30, 2008, from $16.4 million for the same period in 2007. The increase in R&D expenses for both the quarter and nine months ended September 30, 2008, resulted primarily from increased costs associated with our picoplatin clinical trials and pre-clinical programs.

General and administrative (G&A)
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... (PRWEB) March 04, 2015 Vancouver ... recently received two awards in the prestigious Vancouver ... on February 27, 2015. The company secured third ... place in the “Best Registered Massage Therapist” category. ... community newspapers in Canada, The Vancouver Courier is ...
(Date:3/4/2015)... The print component of “Organic Living” ... Chronicle with a circulation of approximately 173,000 copies and ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... composed of heat-dried microbes that have digested the organic ...
(Date:3/4/2015)... 2015 State officials have awarded $82,500 ... of Public Health at Georgia State University, to support ... by Georgia’s Division of Family and Children Services (DFCS) ... Call Center. , The 1-800-CHILDREN Helpline is a ... and referral services that promote the wellbeing of children ...
(Date:3/4/2015)... The Global Liquefied Petroleum Gas Market was ... estimated to grow to $288.7 billion by 2019, ... 2019. , Browse through the TOC of Global ... industry trends, segments & forecasts., http://www.micromarketmonitor.com/market-report/liquid-petroleum-gas-reports-5046983367.html ... is classified into source, application, and region. The ...
(Date:3/4/2015)... Diego, CA (PRWEB) March 04, 2015 ... the launch of their new L-Style Revolution™ Program. The ... for men and women of all health and fitness ... weight maintenance goals faster than traditional methods. , “We’re ... makes available customized plans based on award winning techniques ...
Breaking Medicine News(10 mins):Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2
... Safety council is offering free health and safety qualifications to its members, to 14 – 19 year olds and to those currently not in employment in a bid to increase awareness ... ... ... ...
... Findings could help spur change in how hypertension is ... --Following on recent, similar research, a large five-year study ... a key indicator of stroke risk. , In the ... 19,000 patients taking either beta blockers or calcium channel ...
... is one advance, ,Tommy John, elbow reconstruction another , SUNDAY, ... at the same time as anterior cruciate ligament (ACL) reconstruction ... , Meniscus cartilage acts as a cushion/shock absorber in the ... in the knee. , This study included 99 patients, 18 ...
... levels below currently recommended levels did not ... cardiovascular disease events in adults with type 2 diabetes ... events, according to new results from the landmark Action ... Similarly, treating multiple blood lipids with combination drug therapy ...
... ailment boosts odds for heart attack, stroke, and inflammation ... (HealthDay News) -- The common skin ailment psoriasis may ... cardiovascular woes, probably through a shared inflammatory response, a ... for psoriasis as a risk factor for cardiovascular disease," ...
... researchers say , SATURDAY, March 13 (HealthDay News) -- ... research shows that the performance of female marathoners can ... , Researchers analyzed marathon race results, weather data and ... a period of eight to 28 years. They found ...
Cached Medicine News:Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:More Evidence That Swings in Blood Pressure Raise Stroke Risk 2Health News:Strides Seen in Orthopedic Surgery for Kids 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6Health News:Psoriasis Tied to Raised Heart Risk 2Health News:Air Pollution Slows Women's Marathon Times 2
(Date:3/4/2015)...  Results of the recent study, Results From ... Intra-Operative Positive Margin Detection , were presented as part ... Annual Miami Breast Cancer Conference last week. ... , MD, FACS, Professor of Surgery at the Sackler ... analysis of MarginProbe,s efficiency and accuracy when used consecutively ...
(Date:3/4/2015)... , March 4, 2015  Bayer HealthCare ... Administration (FDA) has accepted the company,s Biologics License ... VIII compound.  Bayer is seeking FDA approval of ... the treatment of hemophilia A in children and ... continually bringing new therapies to hemophilia A patients ...
(Date:3/4/2015)... -- Heska Corporation (Nasdaq: HSKA ) announces the ... Fourth Quarter and Year End 2014 Earnings Conference Call ... (MST) / 11:00 a.m. (EST)Where: www.heska.com (click on ... on the front page of this website)How:Live over the ... the address above.  Alternatively, you may use the following ...
Breaking Medicine Technology:New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
Creatinine Test Kit (enzymatic, liquid reagents), Wavelength: 550 nm. Linear range: up to 150 mg/dL....
For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid....
Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: